Compass Therapeutics, Inc. Common Stock
CMPXCompass Therapeutics, Inc. is a biotechnology company focused on developing innovative immunotherapies for cancer and other diseases. The company utilizes proprietary platform technologies to discover and develop monoclonal antibodies and other biologics aimed at modulating the immune system to combat chronic diseases.
Company News
Compass Therapeutics announced participation in two healthcare investor conferences in December 2025, highlighting their ongoing clinical-stage oncology research focused on antibody-based therapeutics targeting tumor growth and immune system interactions.
Compass Therapeutics will participate in multiple healthcare and investment conferences in September 2025, including events in Boston and New York, presenting their oncology-focused antibody-based therapeutics research.
Compass Therapeutics plans to raise approximately $120 million through a public offering of 33,290,000 common stock shares and pre-funded warrants at $3.00 per share, with the proceeds intended for research, clinical development, and corporate purposes.
Compass Therapeutics plans to launch an underwritten public offering of common stock and pre-funded warrants to fund research, clinical development, and commercial readiness preparations.
Three companies with recent stock rallies that analysts remain bullish on are Compass Therapeutics, Amprius Technologies, and Allot Communications. Analysts see significant upside potential in these momentum stocks despite their recent gains.
